An Israel-based developer of bio-medical materials has secured $27 million for testing on a surgical sealant. The sealant from LifeBond Ltd. is the company's flagship product, the LifeSeal Surgical Sealant. The testing currently funded will help meet United States Food and Drug Administration (FDA) pre-market application requirements and advance commercialization in the European Union. LifeSeal is a two part sealant that depends on gelatin and the microbial transglutaminase enzyme. The enzyme causes the gelatin to very rapidly form a polymer that seals incision sites. Per LifeBond's website, “Both components have been used extensively in the food industry for decades and gelatin-based medical devices have been safely implanted in millions of surgical procedures dating back to the 1950s.” The use of sealant can reduce post-operative complications, such as leakage from incision in gastrointestinal surgeries, thereby reducing infections and other potentially life threatening complications.